2,960 results on '"Yagita, Hideo"'
Search Results
2. Graft Protective and Intercellular Immunomodulatory Effects by Adoptive Transfer of an Agonistic Anti-BTLA mAb (3C10) Induced CD4+CD25+ Regulatory T Cells in Murine Cardiac Allograft Transplant Model
3. Fibroblast growth factor 18 stimulates the proliferation of hepatic stellate cells, thereby inducing liver fibrosis
4. cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis
5. The ATP-hydrolyzing ectoenzyme E-NTPD8 attenuates colitis through modulation of P2X4 receptor–dependent metabolism in myeloid cells
6. Blockade of CD80/CD86-CD28 co-stimulation augments the inhibitory function of peptide antigen-specific regulatory T cells
7. IκBζ controls IL-17-triggered gene expression program in intestinal epithelial cells that restricts colonization of SFB and prevents Th17-associated pathologies
8. cis interaction of CD153 with TCR/CD3 is crucial for the pathogenic activation of senescence-associated T cells
9. Anti-CD80/86 antibodies inhibit inflammatory reaction and improve graft survival in a high-risk murine corneal transplantation rejection model
10. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients
11. Soy isoflavone genistein attenuates the efficacy of immune checkpoint therapy in C57BL/6 mice inoculated with B16F1 melanoma and a high PD-L1 expression level reflects tumor resistance
12. Blockade of tumor necrosis factor superfamily members CD30 and OX40 abrogates disease activity in murine immune-mediated glomerulonephritis
13. Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
14. A high-sensitivity ELISA for detection of human FGF18 in culture supernatants from tumor cell lines
15. Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity
16. PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy
17. Anti-CD321 antibody immunotherapy protects liver against ischemia and reperfusion-induced injury
18. CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer
19. Interleukin-11-expressing fibroblasts have a unique gene signature correlated with poor prognosis of colorectal cancer
20. Impaired Bone Resorption and Woven Bone Formation Are Associated with Development of Osteonecrosis of the Jaw-Like Lesions by Bisphosphonate and Anti–Receptor Activator of NF-κB Ligand Antibody in Mice
21. Regulatory T Cells and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Undergo Fas-Dependent Cell Death during IL-2/αCD40 Therapy
22. Removal of Pre-Existing Periodontal Inflammatory Condition before Tooth Extraction Ameliorates Medication-Related Osteonecrosis of the Jaw–Like Lesion in Mice
23. Corrigendum to ‘Mechanisms of PDL1-mediated regulation of autoimmune diabetes’ [Clin. Immunol. 125 (2007) 16–25]
24. Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance
25. JunB plays a crucial role in development of regulatory T cells by promoting IL-2 signaling
26. Depletion of PD-1-positive cells ameliorates autoimmune disease
27. Modulation of Surgical Fibrosis by Microbial Zwitterionic Polysaccharides
28. Fas-Disabling Small Exocyclic Peptide Mimetics Limit Apoptosis by an Unexpected Mechanism
29. Inducible Costimulator-Dependent IL-10 Production by Regulatory T Cells Specific for Self-Antigen
30. RANKL Inhibition Reduces Cardiac Hypertrophy in mdx Mice and Possibly in Children with Duchenne Muscular Dystrophy
31. Data from Dietary Lactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy
32. Supplementary Figure from Dietary Lactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy
33. Supplementary Table from Dietary Lactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy
34. Supplementary Figure S5 from Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer
35. Supplementary Table 1 from Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer
36. Data from Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer
37. Supplementary Figure Legends from Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer
38. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Induces Neuronal Death in a Murine Model of HIV Central Nervous System Infection
39. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy
40. Requirement for Natural Killer T (NKT) Cells in the Induction of Allograft Tolerance
41. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathway
42. Critical Contribution of Liver Natural Killer T Cells to a Murine Model of Hepatitis
43. Blockade Of PD-1 Attenuated Postsepsis Aspergillosis Via The Activation of IFN-γ and The Dampening of IL-10
44. Targeted Disruption of Traf5 Gene Causes Defects in CD40- and CD27-Mediated Lymphoctye Activation
45. Differential Regulation of Iκ B Kinase α and β by Two Upstream Kinases, NF-κ B-inducing Kinase and Mitogen-Activated Protein Kinase/ERK Kinase Kinase-1
46. Perforin proteostasis is regulated through its C2 domain: supra-physiological cell death mediated by T431D-perforin
47. Supplementary Figure 3 from Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells
48. Supplementary Tables 1 through 3 from Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells
49. Supplementary Figure 1 from Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells
50. Supplementary Figure 2 from Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.